[go: up one dir, main page]

TN2009000345A1 - Aryl carboxylic acid cyclohexyl amide derivatives - Google Patents

Aryl carboxylic acid cyclohexyl amide derivatives

Info

Publication number
TN2009000345A1
TN2009000345A1 TNP2009000345A TN2009000345A TN2009000345A1 TN 2009000345 A1 TN2009000345 A1 TN 2009000345A1 TN P2009000345 A TNP2009000345 A TN P2009000345A TN 2009000345 A TN2009000345 A TN 2009000345A TN 2009000345 A1 TN2009000345 A1 TN 2009000345A1
Authority
TN
Tunisia
Prior art keywords
carboxylic acid
amide derivatives
acid cyclohexyl
aryl carboxylic
cyclohexyl amide
Prior art date
Application number
TNP2009000345A
Other languages
English (en)
Inventor
Rene Hersperger
Philipp Janser
Wolfgang Miltz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2009000345A1 publication Critical patent/TN2009000345A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
TNP2009000345A 2007-02-19 2009-08-17 Aryl carboxylic acid cyclohexyl amide derivatives TN2009000345A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07102622 2007-02-19
PCT/EP2008/051951 WO2008101905A1 (fr) 2007-02-19 2008-02-18 Dérivés cyclohexyl amide d'acide carboxylique aryle

Publications (1)

Publication Number Publication Date
TN2009000345A1 true TN2009000345A1 (en) 2010-12-31

Family

ID=38058317

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000345A TN2009000345A1 (en) 2007-02-19 2009-08-17 Aryl carboxylic acid cyclohexyl amide derivatives

Country Status (35)

Country Link
US (1) US8354431B2 (fr)
EP (1) EP2125782B1 (fr)
JP (1) JP5180234B2 (fr)
KR (1) KR101070984B1 (fr)
CN (1) CN101605781B (fr)
AR (1) AR065369A1 (fr)
AT (1) ATE518854T1 (fr)
AU (1) AU2008219317B2 (fr)
BR (1) BRPI0807625A2 (fr)
CA (1) CA2677565C (fr)
CL (1) CL2008000497A1 (fr)
CR (1) CR10957A (fr)
CY (1) CY1111984T1 (fr)
DK (1) DK2125782T3 (fr)
EA (1) EA017000B1 (fr)
EC (1) ECSP099584A (fr)
ES (1) ES2371126T3 (fr)
GT (1) GT200900226A (fr)
HN (1) HN2009001607A (fr)
HR (1) HRP20110793T1 (fr)
IL (1) IL200191A (fr)
MA (1) MA31206B1 (fr)
MX (1) MX2009008145A (fr)
MY (1) MY147487A (fr)
NZ (1) NZ578663A (fr)
PE (1) PE20081785A1 (fr)
PL (1) PL2125782T3 (fr)
PT (1) PT2125782E (fr)
RS (1) RS51986B (fr)
SI (1) SI2125782T1 (fr)
TN (1) TN2009000345A1 (fr)
TW (1) TW200848038A (fr)
UA (1) UA97389C2 (fr)
WO (1) WO2008101905A1 (fr)
ZA (1) ZA200905160B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
US11591544B2 (en) 2020-11-25 2023-02-28 Akagera Medicines, Inc. Ionizable cationic lipids
CN119562806A (zh) 2022-05-25 2025-03-04 阿卡格拉医药公司 用于递送核酸的脂质纳米粒及其使用方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3532570B2 (ja) 1994-01-13 2004-05-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 哺乳類単球化学誘引物質タンパク質レセプター
EP1482042B1 (fr) 1996-03-01 2009-04-15 Euroscreen S.A. Recepteurs actifs et inactifs de CC-chimiokine et molécules d'acide nucléique encodant celles-ci
EP0975749A2 (fr) * 1996-05-28 2000-02-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Recepteur 5 de cc chemokine, anticorps diriges contre ce dernier et animaux transgeniques
US6388055B1 (en) 1996-10-03 2002-05-14 Smithkline Beecham Corporation Mouse CC-CKR5 receptor polypeptide
AR008331A1 (es) 1997-01-23 1999-12-29 Smithkline Beecham Corp Compuestos antagonistas de un receptor de il-8, uso de los mismos para la fabricacion de medicamentos, procedimiento para su obtencion, composicionesfarmaceuticas que los contienen
EP1039899A2 (fr) * 1997-12-19 2000-10-04 Takeda Chemical Industries, Ltd. Composition pharmaceutique antagoniste de ccr5 et contenant un derive d'anilide
US6312689B1 (en) * 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
CA2353635A1 (fr) * 1998-12-21 2000-06-29 Takeda Chemical Industries, Ltd. Derive de anilide, sa production et son utilisation
WO2001051077A1 (fr) 2000-01-14 2001-07-19 The Government Of The United States Of Americarep Resented By The Secretary, Department Of Health And Human Services Methodes de regulation de la production de il-12 par l'administration d'agonistes et d'antagonistes de ccr5
AU2002212225A1 (en) 2000-09-08 2002-03-22 Micromet Ag Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders
US20050004180A1 (en) 2001-10-03 2005-01-06 ZOU Dong Pyrrolidinone derivatives
AU2003289329A1 (en) * 2002-12-13 2004-07-09 Ono Pharmaceutical Co., Ltd. Antagonist and agonist binding to strong binding site of chemokine receptor
WO2004098638A1 (fr) * 2003-05-06 2004-11-18 Ono Pharmaceutical Co., Ltd. Inhibiteur du fonctionnement de la cellule effectrice
WO2005058234A2 (fr) * 2003-12-11 2005-06-30 Yale University Methodes et compositions relatives a un antagoniste du ccr5, et inflammation induite par ifn-$g(g) et il-13
CN102344398B (zh) * 2003-12-18 2015-02-25 因赛特公司 作为趋化因子受体调控剂的3-环烷基氨基吡咯烷衍生物
GB0403038D0 (en) 2004-02-11 2004-03-17 Novartis Ag Organic compounds
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
BRPI0510665A (pt) * 2004-05-11 2007-12-04 Incyte Corp 3-(4-heteroarilcicloexilamino) ciclopentano-carboxiamidas como moduladores de receptores de quimiocinas
GB0412468D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
US20070149557A1 (en) 2005-11-21 2007-06-28 Amgen Inc. CXCR3 antagonists
GB0525957D0 (en) 2005-12-21 2006-02-01 Astrazeneca Ab Methods
KR20090013827A (ko) 2006-06-12 2009-02-05 화이자 프로덕츠 인크. Ｈｉｖ 환자에서 면역 재구성을 증진시키고 기회 감염을 치료하기 위한 ｃｃｒ５ 길항제
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
CA2665808A1 (fr) 2006-10-05 2008-05-22 Centocor Ortho Biotech Inc. Antagonistes de ccr2 pour le traitement de la fibrose
TW200831497A (en) 2006-10-12 2008-08-01 Epix Delaware Inc Carboxamide compounds and their use
EP2099454A4 (fr) 2006-11-17 2010-11-10 Abbott Lab Aminopyrrolidines utilisés en tant qu'antagonistes du récepteur de la chimiokine
EP2120928A2 (fr) 2007-02-15 2009-11-25 Pfizer Limited Compositions pharmaceutiques et procédés pour la fabrication d'antagonistes ccr5
EP2150817A4 (fr) 2007-04-30 2011-09-07 Progenics Pharm Inc Procédés de réduction de la charge virale chez des patients infectés par le vih-1

Also Published As

Publication number Publication date
HK1138836A1 (en) 2010-09-03
EA200901085A1 (ru) 2010-02-26
PT2125782E (pt) 2011-11-17
ZA200905160B (en) 2010-05-26
CA2677565C (fr) 2014-11-18
WO2008101905A1 (fr) 2008-08-28
HN2009001607A (es) 2011-11-23
TW200848038A (en) 2008-12-16
JP5180234B2 (ja) 2013-04-10
ECSP099584A (es) 2009-09-29
AU2008219317A1 (en) 2008-08-28
CL2008000497A1 (es) 2008-08-29
CN101605781B (zh) 2014-08-13
CR10957A (es) 2009-09-01
AU2008219317B2 (en) 2011-09-08
UA97389C2 (en) 2012-02-10
JP2010519187A (ja) 2010-06-03
CA2677565A1 (fr) 2008-08-28
KR101070984B1 (ko) 2011-10-06
IL200191A0 (en) 2010-04-15
US20100016361A1 (en) 2010-01-21
AR065369A1 (es) 2009-06-03
PL2125782T3 (pl) 2011-12-30
IL200191A (en) 2013-12-31
EP2125782B1 (fr) 2011-08-03
PE20081785A1 (es) 2009-01-12
DK2125782T3 (da) 2011-11-21
EA017000B1 (ru) 2012-09-28
MA31206B1 (fr) 2010-02-01
CN101605781A (zh) 2009-12-16
US8354431B2 (en) 2013-01-15
BRPI0807625A2 (pt) 2014-05-27
RS51986B (sr) 2012-02-29
SI2125782T1 (sl) 2011-12-30
NZ578663A (en) 2011-01-28
CY1111984T1 (el) 2015-11-04
MX2009008145A (es) 2009-08-12
MY147487A (en) 2012-12-14
KR20090103943A (ko) 2009-10-01
ES2371126T3 (es) 2011-12-27
EP2125782A1 (fr) 2009-12-02
ATE518854T1 (de) 2011-08-15
HRP20110793T1 (hr) 2011-11-30
GT200900226A (es) 2010-07-02

Similar Documents

Publication Publication Date Title
TW200740758A (en) Benzoquinazoline derivatives
IL205354A0 (en) Spiroindolinone derivatives
MX2009003081A (es) Derivados de pirrola utiles para el tratamiento de enfermedades mediadas por citoquinas.
TW200801000A (en) Spiroindolinone derivatives
IL193620A0 (en) Spiroindolinone derivatives
BRPI0716598A2 (pt) Derivados de (hetero) arilsulfonamida de n-biarila úteis no tratamento de doenças medidas por interações de linfócitos
IL205506A0 (en) Spiroindolinone derivatives as anticancer agents
TW200612958A (en) Substituted imidazole derivatives
WO2006049835A3 (fr) Derives d'indole et de benzimidazole
UA102518C2 (ru) Способ синтеза ивабрадина и его аддитивных солей с фармацевтически приемлемой кислотой
MX2012003982A (es) Pirrolidinas n-substituidas.
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
EP2581372A4 (fr) Dérivé de cyanoquinoline
PL1753723T3 (pl) Podstawione pochodne chinoliny jako inhibitory kinezyn mitotycznych
UA105527C2 (uk) Сполука-інгібітор матриптази для лікування раку
TN2009000178A1 (en) Substituted pyrazole and triazole compounds as ksp inhibitors
TNSN08369A1 (en) Benzimidazole derivatives
TNSN06220A1 (en) Benzimidazole derivatives
MX2009010483A (es) 5-oxoisoxazoles como inhibidores de lipasas y fosfolipasas.
TN2009000345A1 (en) Aryl carboxylic acid cyclohexyl amide derivatives
WO2006083841A3 (fr) Esters therapeutiques
MY145122A (en) Phenylacetic acid derivatives as cox-2 inhibitors
PH12012502478A1 (en) Isoquinoline derivative
MX2009003640A (es) Derivados de acidos vinilogos como inhibidores de quimasa.